Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Treating Young Patients With Relapsed or Progressive Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: July 26, 2006
Last updated: March 13, 2010
Last verified: July 2009

RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide, celecoxib, and fenofibrate may stop the growth of cancer cells by blocking blood flow to the cancer. Celecoxib also may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with thalidomide, celecoxib, and fenofibrate may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving etoposide and cyclophosphamide together with thalidomide, celecoxib, and fenofibrate works in treating young patients with relapsed or progressive cancer.

Condition Intervention Phase
Brain and Central Nervous System Tumors
Unspecified Childhood Solid Tumor, Protocol Specific
Drug: celecoxib
Drug: cyclophosphamide
Drug: etoposide
Drug: fenofibrate
Drug: thalidomide
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer

Resource links provided by NLM:

Genetic and Rare Diseases Information Center resources: Malignant Mesenchymal Tumor Soft Tissue Sarcoma Leukemia, Myeloid Chronic Myeloid Leukemia Lymphosarcoma Lymphoma, Small Cleaved-cell, Diffuse Acute Lymphoblastic Leukemia Hodgkin Lymphoma Acute Myelocytic Leukemia Acute Non Lymphoblastic Leukemia Neuroblastoma Hodgkin Lymphoma, Childhood Supratentorial Primitive Neuroectodermal Tumor Glioma Burkitt Lymphoma Ependymoma Lymphoma, Large-cell Lymphomatoid Granulomatosis Medulloblastoma Oligodendroglioma Anaplastic Oligodendroglioma Lymphoma, Large-cell, Immunoblastic Plasmablastic Lymphoma Lymphoblastic Lymphoma Small Non-cleaved Cell Lymphoma Neuroepithelioma Anaplastic Large Cell Lymphoma Medulloblastoma, Childhood Cerebellar Astrocytoma, Childhood Brain Stem Glioma, Childhood Pineoblastoma, Childhood Supratentorial Primitive Neuroectodermal Tumors, Childhood Cerebral Astrocytoma, Childhood Chronic Lymphocytic Leukemia Leukemia, B-cell, Chronic Osteosarcoma Bone Cancer Ewing's Sarcoma Ewing's Family of Tumors Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Cutaneous T-cell Lymphoma Angioimmunoblastic T-cell Lymphoma Angioimmunoblastic Lymphadenopathy With Dysproteinemia Mycosis Fungoides Sezary Syndrome Large Granular Lymphocyte Leukemia Brain Tumor, Childhood
U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Time to disease progression [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Tumor response [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
  • Progression-free survival [ Designated as safety issue: No ]
  • Toxicity [ Designated as safety issue: Yes ]
  • Different radiographic techniques as markers of response [ Designated as safety issue: No ]
  • Biological markers as markers of response/angiogenesis [ Designated as safety issue: No ]

Estimated Enrollment: 180
Study Start Date: January 2005
Estimated Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Detailed Description:



  • Evaluate the activity of etoposide, cyclophosphamide, thalidomide, celecoxib, and fenofibrate, in terms of prolonging the time to disease progression, in young patients with relapsed or progressive cancer.


  • Determine, preliminarily, the biologic activity of this regimen, in terms of tumor response and overall survival, in these patients.
  • Determine the toxicity of this regimen in these patients.
  • Evaluate different radiographic techniques as markers of tumor response in these patients.
  • Evaluate the predictive ability of in vitro correlative studies as markers of tumor response.

OUTLINE: This is a multicenter study. Patients are stratified according to disease type (leukemia/lymphoma vs bone tumors [Ewing's sarcoma, osteosarcoma] vs neuroblastoma vs high-grade glial tumors vs low-grade glial tumors vs ependymomas vs medulloblastoma/primitive neuroectodermal tumor [PNET] vs miscellaneous tumors).

Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 180 patients will be accrued for this study.


Ages Eligible for Study:   up to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed cancer (at diagnosis or relapse), including any of the following:

    • Leukemia and/or lymphoma (closed to accrual)
    • Bone tumor (e.g., Ewing's sarcoma or osteosarcoma) (closed to accrual)
    • Neuroblastoma (closed to accrual)
    • High-grade glial tumor
    • Low-grade glial tumor
    • Ependymoma
    • Medulloblastoma and/or primitive neuroectodermal tumor (PNET)
    • Miscellaneous tumor (closed to accrual)
    • Brain stem glioma, defined as intrinsic tumors of the pons causing diffuse enlargement

      • Brain stem glioma that progressed after radiotherapy does not require histological confirmation
      • Duration of symptoms at the time of diagnosis must be < 3 months

        • Symptoms should consist of cranial nerve deficits, ataxia, and/or long tract signs
  • Relapsed or progressive poor prognosis disease for which no available curative therapy exists


  • Karnofsky performance status 50-100% OR Lansky play scale 50-100% (for infants)
  • Life expectancy > 2 months
  • Platelet count > 75,000/mm^3 (transfusion independent)
  • Absolute neutrophil count > 1,000/mm^3 (in patients without bone marrow disease)
  • Hemoglobin ≥ 9.0 g/dL
  • Creatinine < 1.5 mg/dL OR creatinine clearance or glomerular filtration rate ≥ 70 mL/min
  • Bilirubin ≤ 1.5 mg/dL
  • SGPT ≤ 3 times normal
  • SGOT ≤ 3 times normal (4 times normal for patients on ranitidine hydrochloride)
  • Alkaline phosphatase ≤ 3 times normal
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective double-method contraception during and for 2 months after completion of study treatment
  • Must be willing to participate in the Celgene STEPS® program
  • Recent thromboembolic disease (e.g., deep vein thrombosis or pulmonary embolism) allowed if patient is clinically stable and the thromboembolic event occurred > 3 weeks prior to study entry
  • No active infection
  • No active uncontrolled cardiac, hepatic, renal, or psychiatric disease ≥ grade 3
  • No known allergies to sulfonamides
  • No concurrent illness that would obscure toxicity or dangerously alter drug metabolism
  • No other serious medical illness


  • See Disease Characteristics
  • Recovered from prior therapy
  • Prior chemotherapy and/or radiotherapy allowed
  • Prior celecoxib allowed
  • Prior standard-dose IV etoposide and cyclophosphamide administered in 3-week courses allowed
  • No prior oral therapy with etoposide, thalidomide, cyclophosphamide, or fenofibrate for > 2 months in duration
  • No other concurrent investigational agents
  • No other concurrent nonsteroidal anti-inflammatory drugs
  • Concurrent steroids and/or antiseizure medications allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00357500

United States, Connecticut
Connecticut Children's Medical Center
Hartford, Connecticut, United States, 06106
United States, Florida
Miami Children's Hospital
Miami, Florida, United States, 33155-4069
United States, Illinois
Children's Memorial Hospital - Chicago
Chicago, Illinois, United States, 60614
United States, Maine
Maine Medical Center Research Institute
Scarborough, Maine, United States, 04074-7205
United States, Massachusetts
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Minnesota
Children's Hospitals and Clinics of Minnesota - Minneapolis
Minneapolis, Minnesota, United States, 55404
United States, Missouri
St. Louis Children's Hospital
Saint Louis, Missouri, United States, 63110
United States, New Jersey
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08903
United States, New York
NYU Cancer Institute at New York University Medical Center
New York, New York, United States, 10016
United States, Rhode Island
Hasbro Children's Hospital
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
Dana-Farber Cancer Institute
Study Chair: Mark W. Kieran, MD, PhD Dana-Farber Cancer Institute
  More Information

Additional Information:
No publications provided

Responsible Party: Mark William Kieran, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Identifier: NCT00357500     History of Changes
Obsolete Identifiers: NCT00165321
Other Study ID Numbers: CDR0000487628, DFCI-04343
Study First Received: July 26, 2006
Last Updated: March 13, 2010
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
accelerated phase chronic myelogenous leukemia
blastic phase chronic myelogenous leukemia
chronic phase chronic myelogenous leukemia
meningeal chronic myelogenous leukemia
recurrent childhood acute lymphoblastic leukemia
recurrent childhood acute myeloid leukemia
recurrent childhood medulloblastoma
recurrent childhood supratentorial primitive neuroectodermal tumor
recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
recurrent/refractory childhood Hodgkin lymphoma
relapsing chronic myelogenous leukemia
secondary acute myeloid leukemia
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
recurrent osteosarcoma
untreated childhood medulloblastoma
recurrent neuroblastoma
childhood oligodendroglioma
childhood chronic myelogenous leukemia
recurrent childhood brain stem glioma
recurrent childhood visual pathway and hypothalamic glioma
untreated childhood brain stem glioma
untreated childhood visual pathway and hypothalamic glioma
childhood infratentorial ependymoma
childhood supratentorial ependymoma
newly diagnosed childhood ependymoma
recurrent childhood ependymoma
unspecified childhood solid tumor, protocol specific
childhood grade III lymphomatoid granulomatosis
childhood nasal type extranodal NK/T-cell lymphoma

Additional relevant MeSH terms:
Nervous System Neoplasms
Central Nervous System Neoplasms
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms by Site
Nervous System Diseases
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Connective and Soft Tissue
Etoposide phosphate
Immunosuppressive Agents
Immunologic Factors processed this record on August 28, 2014